SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (1419)3/14/2003 1:39:44 PM
From: tuck  Read Replies (2) | Respond to of 3044
 
AACR presentations include some solid tumor data on PS341. Seems as though it will work well with anti cancer agents that induce hypoxia in solid tumors. Use bortezomib as your search term for the relevant abstract.

Cheers, Tuck



To: Miljenko Zuanic who wrote (1419)3/14/2003 2:57:26 PM
From: Ian@SI  Read Replies (1) | Respond to of 3044
 
"Kako sam ti rekao...", odgovori mu SLIJEPI!

Geez, What language is that???? <g>
Does it translate into English?

Re Briefing's comment that 5% of MLNM makes ABT much more valuable, but others shouldn't invest in MLNM, but ABT instead.

The author's logic escaped me.

Ian